Recce Pharmaceuticals Share Price and Company Fundamentals



Price
$1.08
Change
-0.020 (-1.818%)
52 week
0.495 - 1.875

Last traded: Today at 5:56 AM

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Key Metrics

PE ratio

-

PB ratio

8.06

Dividend yield

Beta

1.53

Market cap

$187.68M

Enterprise value

$167.69M

Company profile

Primary activitiesPharmaceutical research and development.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.recce.com.au
Mailing addressGateway Tower Level 36 1 Macquarie Place Sydney NSW 2000 Australia
Phone / Fax61 2 8075 4585 / 61 2 8075 4584
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Recce Pharmaceuticals does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Recce Pharmaceuticals.

NameTitleAgeTotal Pay
Mr. James Hamilton-Bray GrahamCEO & MD215.92k
Ms. Michele Keryn DiliziaChief Scientific Director & Exec. Director217.37k
Dr. Justin WardPrincipal Quality Chemist & Exec. Director164.48k
Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing155.31k
Mr. Justin ReynoldsChief Financial Officer
Mr. Daniel Astudillo B.A., B.Com., M.B.A.Marketing Mang.
Prof. Philip SuttonMember of Clinical Advisory Committee & Head of Helicobacter Pylori Devel. Program
Mr. Alistair McKeough BA, LLB, LLMCompany Sec.

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-1,923.75%

Return on assets

-55.05%

Return on equity

-93.96%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Recce Pharmaceuticals is 187.68M and its enterprise value is 167.69M. The enterprise value to revenue ratio of RCE is 243.01.

The RCE's stocks Beta value is 1.53 making it 53% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Recce Pharmaceuticals (RCE)

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

1. What is Recce Pharmaceuticals's Stock Symbol?

Recce Pharmaceuticals trades on ASX under the ticker symbol "RCE".

2. What is Recce Pharmaceuticals's stock price today?

One share of RCE stock can currently be purchased for approximately $1.08.

3. How can I contact Recce Pharmaceuticals?

Recce Pharmaceuticals's mailing address is Gateway Tower Level 36 1 Macquarie Place Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8075 4585.

4. What is Recce Pharmaceuticals's official website?

The official website of Recce Pharmaceuticals is http://www.recce.com.au.

5. Which share registry manages Recce Pharmaceuticals's stock?

Recce Pharmaceuticals's stock is managed by AUTOMIC REGISTRY SERVICES.